IBERE PHARMACEUTICALS - FORM S-1 - EX-23.1 - EXHIBIT 23.1 - February 8, 2021

Attached files

file filename
S-1 - FORM S-1 - IBERE PHARMACEUTICALStm215210d1_s-1.htm
EX-99.10 - EXHIBIT 99.10 - IBERE PHARMACEUTICALStm215210d1_ex99-10.htm
EX-99.9 - EXHIBIT 99.9 - IBERE PHARMACEUTICALStm215210d1_ex99-9.htm
EX-99.8 - EXHIBIT 99.8 - IBERE PHARMACEUTICALStm215210d1_ex99-8.htm
EX-99.7 - EXHIBIT 99.7 - IBERE PHARMACEUTICALStm215210d1_ex99-7.htm
EX-99.6 - EXHIBIT 99.6 - IBERE PHARMACEUTICALStm215210d1_ex99-6.htm
EX-99.5 - EXHIBIT 99.5 - IBERE PHARMACEUTICALStm215210d1_ex99-5.htm
EX-99.4 - EXHIBIT 99.4 - IBERE PHARMACEUTICALStm215210d1_ex99-4.htm
EX-99.3 - EXHIBIT 99.3 - IBERE PHARMACEUTICALStm215210d1_ex99-3.htm
EX-99.2 - EXHIBIT 99.2 - IBERE PHARMACEUTICALStm215210d1_ex99-2.htm
EX-99.1 - EXHIBIT 99.1 - IBERE PHARMACEUTICALStm215210d1_ex99-1.htm
EX-14 - EXHIBIT 14 - IBERE PHARMACEUTICALStm215210d1_ex14.htm
EX-10.8 - EXHIBIT 10.8 - IBERE PHARMACEUTICALStm215210d1_ex10-8.htm
EX-10.7 - EXHIBIT 10.7 - IBERE PHARMACEUTICALStm215210d1_ex10-7.htm
EX-10.6 - EXHIBIT 10.6 - IBERE PHARMACEUTICALStm215210d1_ex10-6.htm
EX-10.5 - EXHIBIT 10.5 - IBERE PHARMACEUTICALStm215210d1_ex10-5.htm
EX-10.4 - EXHIBIT 10.4 - IBERE PHARMACEUTICALStm215210d1_ex10-4.htm
EX-10.3 - EXHIBIT 10.3 - IBERE PHARMACEUTICALStm215210d1_ex10-3.htm
EX-10.2 - EXHIBIT 10.2 - IBERE PHARMACEUTICALStm215210d1_ex10-2.htm
EX-10.1 - EXHIBIT 10.1 - IBERE PHARMACEUTICALStm215210d1_ex10-1.htm
EX-5.2 - EXHIBIT 5.2 - IBERE PHARMACEUTICALStm215210d1_ex5-2.htm
EX-5.1 - EXHIBIT 5.1 - IBERE PHARMACEUTICALStm215210d1_ex5-1.htm
EX-4.4 - EXHIBIT 4.4 - IBERE PHARMACEUTICALStm215210d1_ex4-4.htm
EX-4.3 - EXHIBIT 4.3 - IBERE PHARMACEUTICALStm215210d1_ex4-3.htm
EX-4.2 - EXHIBIT 4.2 - IBERE PHARMACEUTICALStm215210d1_ex4-2.htm
EX-4.1 - EXHIBIT 4.1 - IBERE PHARMACEUTICALStm215210d1_ex4-1.htm
EX-3.2 - EXHIBIT 3.2 - IBERE PHARMACEUTICALStm215210d1_ex3-2.htm
EX-3.1 - EXHIBIT 3.1 - IBERE PHARMACEUTICALStm215210d1_ex3-1.htm
EX-1.1 - EXHIBIT 1.1 - IBERE PHARMACEUTICALStm215210d1_ex1-1.htm

 

Exhibit 23.1

 

Independent Registered Public Accounting Firm’s Consent

 

 

We consent to the inclusion in this Registration Statement of Ibere Pharmaceuticals (the “Company”) on Form S-1 of our report dated February 8, 2021, which includes an explanatory paragraph as to the Company’s ability to continue as a going concern, with respect to our audit of the financial statements of the Company as of December 31, 2020 and for the period from October 22, 2020 (inception) through December 31, 2020, which report appears in the Prospectus, which is part of this Registration Statement. We also consent to the reference to our Firm under the heading “Experts” in such Prospectus.

 

 

/s/ Marcum llp

 

Marcum llp

New York, NY

February 8, 2021